FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment
연구 도서관으로 돌아가기

Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment

In a significant development for peptide research and obesity management, Novo Nordisk A/S has initiated a clinical study aimed at comparing two versions of cagrilintide in adults with overweight or obesity. This Phase 1 trial seeks to understand the pharmacokinetic profiles of different formulations of this promising therapeutic agent.

Background

Cagrilintide is an investigational glucagon-like peptide-2 (GLP-2) receptor antagonist that has shown promise in reducing food intake and body weight in preclinical studies. It operates by blocking the GLP-2 hormone, which stimulates appetite and nutrient absorption. The drug's potential to aid in obesity management makes it a subject of intense interest within the medical community.

Novo Nordisk, already well-known for its research into diabetes treatments like semaglutide (which has also shown efficacy in weight loss), is expanding its scope with cagrilintide. This new study aims to clarify which formulation of cagrilintide might be more effective and safer for long-term use among individuals struggling with excess weight.

Key Details

The research, officially titled "A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity," is now listed on ClinicalTrials.gov (NCT07597018). The trial will involve participants receiving either cagrilintide version D, version B, or a placebo semaglutide I. Treatment allocation will be random and double-blind to ensure unbiased results.

The study duration spans six months, during which researchers will meticulously monitor blood levels of the drug to assess its pharmacokinetic properties. This information is crucial for determining optimal dosing regimens and identifying potential side effects early on.

Key Takeaways

  • Comparative Analysis: The trial aims to compare two distinct formulations of cagrilintide to ascertain which one offers better efficacy and safety.
  • Long-term Study Design: With a study duration of six months, researchers can gain insights into the drug's long-term effects on weight management.
  • Randomized Allocation: Participants will be randomly assigned to receive either cagrilintide D or B or a placebo semaglutide I, ensuring unbiased results.
  • Pharmacokinetic Data: Comprehensive blood level monitoring over six months will provide critical pharmacokinetic data for further development of the drug.

What This Means

This study is pivotal in advancing peptide therapy for obesity management. By comparing different formulations of cagrilintide, researchers hope to identify a version that maximizes therapeutic benefits while minimizing risks. As such, this research not only contributes to the scientific understanding of GLP-2 receptor antagonists but also opens avenues for future clinical applications.

For the broader peptide community, this development underscores the ongoing commitment to discovering innovative treatments for obesity and metabolic disorders. The results from this trial could influence regulatory approvals and pave the way for new therapeutic options that address unmet medical needs in weight management.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.